Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We recently identified a novel gene (
PB39
) (HGMW-approved symbol POV1) whose expression is up-regulated in human
prostate cancer
using tissue microdissection-based differential display analysis. In the present study we report the full-length sequencing of
PB39
cDNA, genomic localization of the
PB39
gene, and genomic sequence of the mouse homologue. The full-length human cDNA is 2317 nucleotides in length and contains an open reading frame of 559 amino acids which does not show homology with any reported human genes. The N-terminus contains charged amino acids and a helical loop pattern suggestive of an srp leader sequence for a secreted protein. Fluorescence in situ hybridization using
PB39
cDNA as probe mapped the gene to chromosome 11p11.1-p11.2. Comparison of
PB39
cDNA sequence with murine sequence available in the public database identified a region of previously sequenced mouse genomic DNA showing 67% amino acid sequence homology with human
PB39
. Based on alignment and comparison to the human cDNA the mouse genomic sequence suggests there are at least 14 exons in the mouse gene spread over approximately 100 kb of genomic sequence. Further analysis of
PB39
expression in human tissues shows the presence of a unique splice variant mRNA that appears to be primarily associated with fetal tissues and tumors. Interestingly, the unique splice variant appears in prostatic intraepithelial neoplasia, a microscopic precursor lesion of
prostate cancer
. The current data support the hypothesis that
PB39
plays a role in the development of human
prostate cancer
and will be useful in the analysis of the gene product in further human and murine studies.
...
PMID:cDNA sequencing and analysis of POV1 (PB39): a novel gene up-regulated in prostate cancer. 972 52